Libord Finance is a non-banking financial company that provides working capital loans, project financing, and corporate advisory services to small and medium-sized enterprises in India.
The company lacks a durable competitive advantage, as evidenced by extremely low average ROCE (1.6%) and ROE (1.1%), which are significantly below the cost of capital. There is no evidence of brand power, switching costs, or scale advantages that would allow for excess returns in the highly competitive Indian lending market.
Management has failed to generate meaningful returns on equity, with capital largely tied up in low-yielding loans and investments. The lack of dividends despite a lack of high-return reinvestment opportunities suggests a poor grasp of value creation for minority shareholders.
The investment collapsed as the massive gap between the market price and intrinsic value finally closed, driven by a total lack of earnings power. Over five years, the stagnant revenue growth failed to keep pace with inflation, while the operational losses observed in 2025 became a recurring theme. The capital tied up in low-yielding associate company loans never generated a return above the cost of capital, and the frequent reversal of bad debt provisions eventually exhausted the reserves, leaving the company as a hollow shell of unproductive assets.
RichFakir rates Libord Finance Ltd's business quality as poor — 24/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Libord Finance Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Libord Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Libord Finance Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →